Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (891)	4/23/2001 8:59:31 AM
From: GeoDude	Read Replies (1) \| Respond to of 1475

To my untrained eye, the following appears like competition for BTRN. Any trained opinions? Isotechnika Inc. to present trial results of its lead drug ISA(TX)247 at International medical/scientific meetings Pre-clinical and Phase 1 human clinical trial results to be presented at several key International conferences www.isotechnika.com Toronto Stock Exchange: ISA EDMONTON, AB, April 23 /CNW/ - Isotechnika Inc., a innovative life sciences company specializing in the research and development of novel immunosuppressive drugs for prevention of organ rejection after transplantation and for the treatment of autoimmune diseases such as psoriasis, rheumatoid arthritis and type 1 diabetes, today announced that the Company has been invited to present papers detailing the results for its immunosuppressive drug ISA(TX)247 at several key Medical Scientific/Meetings over the next several months. The Company will present: - One paper at the International Society for Heart and Lung Transplantation Meeting to be held in Vancouver Canada from April 25- 28, 2001. - Five papers including one symposium presentation at the American Society for Transplantation Meeting to be held in Chicago May 12-16, 2001. - Five papers including one symposium presentation at the International Congress of Therapeutic Drug Monitoring and Clinical Toxicology to be held in Washington D.C. September 1-6,2001. "All the submitted papers underwent detailed scientific peer review prior to acceptance. With an acceptance rate of less than 20% for some of the meetings, the fact that all the submitted papers were accepted for presentation lends support to the quality of the data obtained for ISA(TX)247." said Dr. Randall Yatscoff, President of Isotechnika. "An important scientific milestone for a new drug is to obtain acceptance of the data by peers. We feel that this has been achieved; moreover, this high acceptance rate further supports the continued work performed by our scientific team." The Company's lead drug, ISA(TX)247, is a novel immunosuppressive drug designed for the prevention of organ rejection after transplantation, and for treatment of autoimmune diseases such as arthritis and psoriasis. Pre-clinical and Phase 1 studies in humans for ISA(TX)247 have revealed superior efficacy and reduced toxicity when compared with current gold standard medications such as cyclosporine. Annual worldwide sales of cyclosporine exceed C$2 billion. The applications to commence Phase II trials for the drug in renal transplantation were recently filed with the Food and Drug Administration of the United States and the Health Protection Branch of the Government of Canada. About Isotechnika Isotechnika is a life-sciences company located in Edmonton. Its lead drug is ISA(TX)247. Isotechnika also globally markets and distributes a breath test diagnostic product line, which it has developed. One of these products, the Helikit, is the gold standard for the diagnosis of ulcers.